Document is current
Any future updates will be listed below
-
Authors
Wu, Lawrence W.
Deshmukh, Sachin Kumar
Wu, Sharon
Xiu, Joanne
Jang, Sung Joo
Park, Jimyung
Lam, Vincent K.
Lou, Emil
Goel, Sanjay
Shroff, Rachna T.
Moy, Ryan H.
-
Funding
Funding for this research was provided by:
National Cancer Institute (5T32CA203703)
National Cancer Institute (K08CA263304)
American Association for Cancer Research (23-80-41-MOY)
Congressionally Directed Medical Research Programs (HT9425-24-1-0419)
- License Information
-
More Information
Article History
Received: 17 December 2024
Accepted: 24 June 2025
First Online: 17 July 2025
Competing interests
: L.W.W., S.J., J.P., and S.G. declare no competing interests. S.K.D., S.W., and J.X. are employees of Caris Life Sciences. V.K.L. has served in a consultant/advisory role for Pfizer, Genentech/Roche, Iovance Biotherapeutics, Anheart Therapeutics, Takeda, Seattle Genetics, Bristol Myers Squibb, AstraZeneca and Guardant Health, and has received research funding from GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca, Merck and Seattle Genetics. R.T.S. has served in a consult/advisory role for AstraZeneca, Boehringer Ingelheim Pharma, Clovis, Genentech, Incyte, Merck, QED Therapeutics, Servier, Taiho, Zymeworks Biopharm, Syros, Astellas, Natera, Hoopika Pharma, Abbvie, Duo Oncology, and has received research funding from Bayer, Bristol Myers Squibb, Exelixis Pharmaceuticals, IMV Inc, LOXO, Novocure, NUCANA, Pieris, Rafael Pharmaceuticals, Seagen. R.H.M. has served in a consult/advisory role for Puretech Health, IDEAYA Biosciences, Nimbus Therapeutics, and Amgen; and has received research funding from Nimbus Therapeutics and Repare Therapeutics.
